SheJLiuLLiuW. COVID-19 epidemic: disease characteristics in children. J Med Virol. 2020;92:747-754.
2.
CDC COVID-19 Response Team. Coronavirus disease 2019 in children—United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:422-426.
3.
CastagnoliRVottoMLicariA, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020;174:882-889.
4.
DongYMoXHuY, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145:e20200702.
5.
HasanAMehmoodNFergieJ. Coronavirus disease (COVID-19) and pediatric patients: a review of epidemiology, symptomatology, laboratory and imaging results to guide the development of a management algorithm. Cureus. 2020;12:e7485.
6.
ZimmermannPCurtisN. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020;39:355-368.
7.
YagnikPJUmscheidJKhanAWAliMBhattPDesaiPH. Pediatric characteristics of 2019 novel coronavirus: review of available published literature. Clin Pediatr (Phila). 2020;59:849-852.
8.
GefenAMPalumboNNathanSKSingerPSCastellanos-ReyesLJSethnaCB. Pediatric COVID-19-associated rhabdomyolysis: a case report. Pediatr Nephrol. 2020;35:1517-1520.
9.
SuwanwongseKShabarekN. Rhabdomyolysis as a presentation of 2019 novel coronavirus disease. Cureus. 2020;12:e7561.
10.
JinMTongQ. Rhabdomyolysis as potential late complication associated with COVID-19. Emerg Infect Dis. 2020;26:1618-1620.
11.
ChanKHFaroujiIHanoudAASlimJ. Weakness and elevated creatinine kinase as the initial presentation of coronavirus disease 2019 (COVID-19). Am J Emerg Med. 2020;38:1548.e1-1548.e3.
12.
MannixRTanMLWrightRBaskinM. Acute pediatric rhabdomyolysis: causes and rates of renal failure. Pediatrics. 2006;118:2119-2125.
13.
PesikNTOttenEJ. Severe rhabdomyolysis following a viral illness: a case report and review of the literature. J Emerg Med. 1996;14:425-428.
14.
O’ConnorJVIyerSK. Myoglobinuria associated with parainfluenza type 2 infection. N Y State J Med. 1982;82:1469-1470.
15.
UedaKRobbinsDAIitakaKLinnemannCCJr.Fatal rhabdomyolysis associated with parainfluenza type 3 infection. Hiroshima J Med Sci. 1978;27:99-103.
16.
RunnstromMEbiedAMKhouryAPReddyR. Influenza-induced rhabdomyolysis. BMJ Case Rep. 2018;11:e226610.
17.
SatoENakamuraTKoideH. Rhabdomyolysis induced by influenza A infection: case report and review of literature. Ther Apher Dial. 2011;15:208-209.
18.
McMahonGMZengXWaikarSS. A risk prediction score for kidney failure or mortality in rhabdomyolysis. JAMA Intern Med. 2013;173:1821-1828.
19.
ZhangCWuZLiJWZhaoHWangGQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55:105954.
20.
ChowEJSedivaI. Influenza A infection and anaphylaxis in a pediatric patient hospitalized for asthma exacerbation. R I Med J (2013). 2017;100:35-36.
21.
TheoharidesTCAlysandratosKDAngelidouA, et al. Mast cells and inflammation. Biochim Biophys Acta. 2012;1822:21-33.
22.
KulkaMBefusAD. The dynamic and complex role of mast cells in allergic disease. Arch Immunol Ther Exp (Warsz). 2003;51:111-120.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
